spacer
home > ebr > winter 2002 > target validation in the nervous system using herpes simplex viral vectors
PUBLICATIONS
European Biopharmaceutical Review

Target Validation in the Nervous System using Herpes Simplex Viral Vectors

The recent sequencing of the human genome has produced a plethora of potential novel drug targets and candidate genes for gene therapy. New drug discovery using large-scale functional genomics approaches, however, faces the major problem of target validation. Traditionally this has been achieved by pharmacology, using specific antagonists and agonists, or by using transgenic animals, particularly knock-out mice. However, these approaches have considerable drawbacks, being extremely time-consuming, laborious and expensive. This is particularly the case if large numbers of potential target genes are to be tested.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr James Palmer, Senior Scientist, and Dr Robert Coffin, Chief Scientific Officer, at BioVex Ltd Dr James Palmer joined BioVex Ltd, a gene delivery and therapeutic vaccine company, in September 1999. He was previously a post-doctoral fellow at University College London in the academic laboratory of BioVex's Founding Scientist and current Research Director, Dr Robert Coffin.
Dr Palmer is currently a Senior Scientist developing herpes simplex viral vector systems for gene delivery to the nervous system for target validation purposes. Prior to this, he obtained his PhD in Molecular Neuroscience from the University of Cambridge working in the Neurobiology Division of the MRC Laboratory of Molecular Biology, and his BSc in Pharmacology from the University of Bristol.

Dr Robert Coffin is a Founding Scientist at Biovex Ltd, Lecturer in Virology and Gene Therapy at University College London (UCL) and Honorary Senior Lecturer at The Institute of Child Health. Following a PhD in Virology at Imperial College, Dr Coffin moved to UCL to develop herpes simplex virus (HSV) based vectors and to study the molecular basis of HSV latency.

During the course of this work - which led to the foundation of Biovex Ltd where he is CSO - vectors were developed that are useful for studying, and potentially treating, neurological disease and for the immune-based treatment of various diseases. Dr Coffin is a world recognised expert in the field of HSV vectorology and latency, and has authored numerous scientific publications.


spacer
Dr James Palmer
spacer
spacer
spacer
Dr Robert Coffin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Medpace Reference Laboratories establishes state of the art Flow Cytometry techniques for flexible approaches to clinical trials across multiple therapeutic areas.

Medpace

Cytometry is the process of measuring the properties of individual cells. These properties may include gene or protein expression, chemical properties, deoxyribonucleic acid (DNA) content, and various cellular functions. The earliest methods of cytometry relied upon light microscopy for the classification and observation of cells and cellular components. Microscopy permitted direct visual observation of cells for the first time, leading to the classification of cells by morphology and insight into cellular functions. However, the time required for microscopic analysis constrains the number of samples or number of cells in each sample that can be examined. Therefore, the utility of microscopy for analysis of rare cells or in situations where sample throughput is a priority is limited. Flow cytometry was developed largely to improve upon these limitations.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement